ALK-Abelló A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKBLF research report →
About the company
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe, North America, and other international regions. These offerings include immunotherapy products delivered through injections, sublingual drops, and oral tablets, designed to address various allergies such as those caused by house dust mites, grass, tree, ragweed, and Japanese cedar.
- CEO
- Peter Halling
- IPO
- 2009
- Employees
- 2,736
- HQ
- Horsholm, DK
Price Chart
- Market Cap
- $8.18B
- P/E
- 42.29
- P/S
- 8.24
- P/B
- 8.23
- EV/EBITDA
- 25.03
- Div Yield
- 0.66%
- Gross Margin
- 67.76%
- Op Margin
- 26.73%
- Net Margin
- 19.51%
- ROE
- 20.45%
- ROIC
- 16.25%
- Revenue
- $6.30B · 13.74%
- Net Income
- $1.19B · 46.54%
- EPS
- $5.41 · 47.01%
- Op Income
- $1.66B
- FCF YoY
- 1808.34%
- 52W High
- $40.65
- 52W Low
- $28.20
- 50D MA
- $38.28
- 200D MA
- $35.02
- Beta
- 0.72
- Avg Volume
- 56
Get TickerSpark's AI analysis on AKBLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AKBLF coverage
Recent articles, reports, and earnings notes.
No research on AKBLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AKBLF report →Similar companies
Peers in the same neighborhood.